嵌合抗原受體巨噬細胞 (CAR-M) 免疫療法:流行病學的考察 (到2030年)

本報告提供全球主要國家 - 美國，歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國) 、日本 - 的嵌合抗原受體巨噬細胞 (CAR-M) 免疫療法的疫情趨勢與今後的預測 (過去3年、今後11年份) 分析。

目錄

第1章 主要考察

第2章 嵌合抗原受體巨噬細胞 (CAR-M) 免疫療法:摘要整理

第3章 CAR-M免疫療法:疾病的背景和概要

• 簡介
• 徵兆與症狀
• 病理生理學
• 危險因素
• 診斷方法

第4章 病患歷程

第5章 流行病學和患者人口

• 流行病學分析的要點
• 假設和理論的根據:主要7個國家
• 流行病學方案:主要7個國家
  • CAR-M免疫療法:主要7個國家的流行病學方案 (2017年∼2030年)
• 美國的疫情趨勢
  • 美國國內的CAR-M免疫療法的流行病學方案 (2017年∼2030年)
• 歐洲5個國家:各國疫情趨勢
  • 德國的疫情趨勢
  • 法國的疫情趨勢
  • 義大利的疫情趨勢
  • 西班牙的疫情趨勢
  • 英國的疫情趨勢
• 日本的疫情趨勢
  • 日本國內的CAR-M免疫療法的流行病學方案 (2017年∼2030年)

第6章 治療流程，目前治療、診療方法

• CAR-M免疫療法的治療、管理方法
• CAR-M免疫療法的治療流程

第7章 產業專家 (KOL)的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

DelveInsight's 'Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Understanding

The DelveInsight Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology report gives a thorough understanding of the Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy in the US, Europe, and Japan. The report covers the detailed information of the Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology scenario in seven major countries (US, EU5, and Japan).

Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Perspective by DelveInsight

The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Detailed Epidemiology Segmentation

The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology covered in the report provides historical as well as forecasted Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

• The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Report and Model provide an overview of the risk factors and global trends of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy
• The report provides the segmentation of the Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology

Report Highlights:

• 11-Year Forecast of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology
• 7MM Coverage
• Total Cases of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy
• Total Cases of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy according to segmentation
• Diagnosed cases of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy?
• What are the key findings pertaining to the Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy?
• What are the currently available treatments of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy?

Reasons to buy:

• The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy market
• Quantify patient populations in the global Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy therapeutics in each of the markets covered
• Understand the magnitude of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy population by its epidemiology
• The Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

3. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy : Disease Background and Overview

• 3.1. Introduction
• 3.2. Sign and Symptoms
• 3.3. Pathophysiology
• 3.4. Risk Factors
• 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

• 5.1. Epidemiology Key Findings
• 5.2. Assumptions and Rationale: 7MM
• 5.3. Epidemiology Scenario: 7MM
  • 5.3.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in the 7MM (2017- 2030)
• 5.4. United States Epidemiology
  • 5.4.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in the United States (2017- 2030)
• 5.5. EU-5 Country-wise Epidemiology
  • 5.5.1. Germany Epidemiology
    • 5.5.1.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in Germany (2017- 2030)
  • 5.5.2. France Epidemiology
    • 5.5.2.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in France (2017- 2030)
  • 5.5.3. Italy Epidemiology
    • 5.5.3.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in Italy (2017- 2030)
  • 5.5.4. Spain Epidemiology
    • 5.5.4.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in Spain (2017- 2030)
  • 5.5.5. United Kingdom Epidemiology
    • 5.5.5.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in the United Kingdom (2017-2030)
• 5.6. Japan Epidemiology
  • 5.6.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

• 6.1. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Treatment and Management
• 6.2. Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

• 9.1. Bibliography
• 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

• Table 1: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in 7MM (2017-2030)
• Table 2: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in 7MM (2017-2030)
• Table 3: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in the United States (2017-2030)
• Table 4: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in the United States (2017-2030)
• Table 5: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Germany (2017-2030)
• Table 6: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Germany (2017-2030)
• Table 7: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in France (2017-2030)
• Table 8: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in France (2017-2030)
• Table 9: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Italy (2017-2030)
• Table 10: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Italy (2017-2030)
• Table 11: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Spain (2017-2030)
• Table 12: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Spain (2017-2030)
• Table 13: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in the United Kingdom (2017-2030)
• Table 14: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Table 15: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Japan (2017-2030)
• Table 16: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

• Figure 1: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in 7MM (2017-2030)
• Figure 2: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in 7MM (2017-2030)
• Figure 3: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in the United States (2017-2030)
• Figure 4: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in the United States (2017-2030)
• Figure 5: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Germany (2017-2030)
• Figure 6: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Germany (2017-2030)
• Figure 7: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in France (2017-2030)
• Figure 8: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in France (2017-2030)
• Figure 9: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Italy (2017-2030)
• Figure 10: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Italy (2017-2030)
• Figure 11: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Spain (2017-2030)
• Figure 12: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Spain (2017-2030)
• Figure 13: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in the United Kingdom (2017-2030)
• Figure 14: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Figure 15: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Epidemiology in Japan (2017-2030)
• Figure 16: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report